Identification of Biomarkers in Subjects With Coronary Syndrome (PLAQUE Study)

Launched by ISTITUTO NAZIONALE DI RICOVERO E CURA PER ANZIANI · Oct 23, 2023

Keywords

ClinConnect Summary

The PLAQUE Study is a clinical trial aimed at understanding how certain substances in the blood, known as biomarkers, can help identify patients with coronary syndrome. This study focuses on patients who are undergoing a procedure called angioplasty, which is a common treatment for narrowing of the heart's arteries. Researchers will examine levels of innovative biomarkers, including miRNAs, in the blood of participants to see how they relate to their heart condition.

To be eligible for this study, participants should be between 65 and 74 years old and have a medical need for the angioplasty procedure, as guided by leading heart health experts. Candidates must have specific types of blockages in key heart vessels and should not have certain medical issues, such as severe kidney problems or contraindications to blood-thinning medications. Those who join the study can expect to provide blood samples during their treatment, and their data will help improve understanding of heart disease and potentially lead to better care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical indication for the PCI procedure according to the latest ESC (European Society of Cardiology) Guidelines
• • Coronary stenosis treated with angioplasty must be located in the proximal segments of the three main vessels: IVA, CX and CD
• • The vessels must have a diameter of their mid-distal section ≥ 3 mm
• • Patients with NSTEMI ACS and clinical indication with favorable anatomy for coronary angioplasty, also called percutaneous coronary intervention (PCI), (for the ACS group)
• • Patients with clinically incipient SCC with stable angina (or significant anginal equivalents) and clinical indication with favorable anatomy for PCI (for the SCC group)
• Exclusion Criteria:
• • Contraindications to anticoagulant/antiplatelet therapy
• • Extensive calcifications and/or tortuosity of the major epicardial segments
• • Evidence of thrombotic occupation
• • Patients with hemodynamic instability
• • Patients with EF (ejection fraction) \< 35%
• • Patients with severe chronic renal failure (e-GFR \< 30 mL/min)